Centre d'Esclerosi Múltiple de Catalunya, CEM-Cat, Unitat de Neuroimmunologia Clínica, Hospital Universitari Vall d'Hebron, Passeig Vall d'Hebron 119-129, Barcelona, Spain.
J Neuroimmunol. 2011 Oct 28;239(1-2):101-4. doi: 10.1016/j.jneuroim.2011.08.004. Epub 2011 Sep 1.
Recent studies have revealed an association between interleukin 28B (IL28B) and response to IFN-alpha treatment in hepatitis C patients. Here we investigated the influence of IL28B polymorphisms in the response to interferon-beta (IFNβ) in multiple sclerosis (MS) patients. We genotyped two SNPs of the IL28B gene (rs8099917 and rs12979860) in 588 MS patients classified into responders (n=281) and non-responders (n=307) to IFNβ. Combined analysis of the study cohorts showed no significant associations between SNPs rs8099917 and rs12979860 and the response to treatment. These findings do not support a role of IL28B polymorphisms in the response to IFNβ in MS patients.
最近的研究揭示了白细胞介素 28B（IL28B）与丙型肝炎患者对干扰素-α治疗反应之间的关联。在这里，我们研究了白细胞介素 28B 基因多态性（IL28B）在多发性硬化症（MS）患者对干扰素-β（IFNβ）反应中的影响。我们对 588 名多发性硬化症患者（分为应答者（n=281）和无应答者（n=307））的 IL28B 基因的两个 SNP（rs8099917 和 rs12979860）进行了基因分型。对研究队列的综合分析表明，SNP rs8099917 和 rs12979860 与治疗反应之间没有显著关联。这些发现不支持白细胞介素 28B 多态性在多发性硬化症患者对 IFNβ 反应中的作用。
Zotero 插件